
Background and Objectives: The aim of this study was to determine whether systemic immunosuppression increases postoperative endophthalmitis risk following cataract surgery and to characterize risk differences across immunosuppressant medication classes. Patients and Methods: Retrospective cohort study using the TriNetX federated health research network identified 422,786 immunosuppressed patients (medication exposure within 90 days pre-surgery) and 263,913 non-immunosuppressed patients undergoing cataract surgery. After 1:1 propensity score matching for age, sex, race, diabetes, ethnicity, autoimmune diagnosis, year of surgery, and prior intravitreal injections, 208,935 patients remained per cohort. Patients were identified using International Classification of Diseases, Tenth Revision (ICD-10) and Current Procedural Terminology (CPT) codes, with medications categorized as corticosteroids, classic non-biologic immunosuppressants, small molecule inhibitors, or biologic immunomodulators. Endophthalmitis outcomes were assessed at 1 to 42 days (acute), 43 to 365 days (delayed onset), and 1 to 90 days postoperatively. Results: Immunosuppressed patients showed significantly elevated 90-day endophthalmitis risk (odds ratio [OR] 1.77, 95% CI 1.42–2.21, P < .0001; risk difference 0.128%). Risk elevation persisted for acute (OR 1.86, 95% CI 1.52–2.24, P < .0001) and delayed (OR 2.07, 95% CI 1.51–2.84, P < .0001) timeframes. Classic non-biologic immunosuppressants demonstrated strongest association (OR 5.03, 95% CI 3.97–6.37, P < .0001), followed by systemic corticosteroids (OR 1.77, 95% CI 1.40–2.23, P < .0001). Small molecule inhibitors showed non-significant trends. Biologic immunomodulators demonstrated a lower observed risk for acute endophthalmitis (OR 0.58, 95% CI 0.41–0.81, P = .0015). Conclusion: Systemic immunosuppression significantly increases acute and delayed-onset postoperative endophthalmitis risk following cataract surgery, with substantial variation across medication classes. Classic immunosuppressants and corticosteroids confer the highest risk, whereas biologic immunomodulators do not appear to increase risk.
Background and Objective: The purpose of this study was to characterize the association between geographic atrophy (GA) growth and age-related macular degeneration (AMD) drusen phenotype. Patients and Methods: This retrospective cohort study included 59 eyes from 47 patients over 55 years with GA, followed for up to 5 years. Eyes with poor-quality imaging, irregular follow-up, or exudation were excluded. Based on multimodal retinal imaging, eyes were classified into three groups: Group 1 (reticular pseudodrusen [RPD]), Group 2 (large soft drusen [LSD]), and Group 3 (mixed RPD and LSD). Fundus autofluorescence (FAF) images were analyzed from baseline to 60 months. GA lesion area and growth rate were measured semi-automatically using Region-Finder (Heidelberg Engineering) and compared across groups over time. Results: The mean baseline GA area was 1.2 ± 0.8 mm 2 . The overall mean GA growth rate was 1.5 ± 0.9 mm 2 /year. Group 1 (RPD) showed the fastest progression at 2.56 ± 1.09 mm 2 /year, significantly higher than Group 2 (LSD, 1.02 ± 0.80 mm 2 /year) and Group 3 (1.10 ± 0.81 mm 2 /year) ( P < .005). No significant difference was observed between Groups 2 and 3 ( P = .28). These differences remained consistent at months 12, 24, 36, 48, and 60. Conclusion: GA progression is significantly faster in eyes with pure RPD phenotype. Mixed phenotype behaves similarly to LSD, supporting phenotype-specific monitoring and treatment strategies.
Background and Objective: The purpose of this study was to evaluate the efficacy of high-dose aflibercept 8 mg in the treatment of diabetic macular edema (DME) refractory to faricimab-svoa treatment. Patients and Methods: This retrospective study included 82 eyes from 64 patients with DME previously treated with faricimab-svoa. Injection intervals, corrected or pinhole visual acuity (VA), and central foveal thickness (CFT) were recorded. Results: Between the time of switch to the fifth injection, the average (SD) injection interval increased from 63 (45) days to 69 (23) days ( P = .01). Mean VA decreased from 58.1 (23.1) to 52.9 (22.7) letters ( P = .263), and average CFT decreased from 360 (145) µm to 348 (151) µm ( P = .626). Intraretinal fluid incidence decreased from 50% to 33.3% ( P = .066), while subretinal fluid incidence increased from 6.1% to 14.8% ( P = .308). Conclusion: Anatomic and visual changes were not significant following switch to aflibercept 8 mg. Sustained injection interval improvements were present at the final aflibercept 8 mg injection.
Background and Objective: The purpose of this study was to assess the association between patient age and two high-risk molecular features in uveal melanoma (UM): class 2 gene expression profile (GEP) and positive preferentially expressed antigen in melanoma (PRAME) expression status. Patients and Methods: This retrospective study included 481 UM patients who underwent molecular profiling. Multivariate logistic regression evaluated associations between GEP class 2 or positive PRAME expression status and demographic and clinical features. Nonlinear effects of age on GEP class were assessed using a 3-knot restricted cubic spline. A multivariable model using age cohorts was employed to examine GEP class 2 risk across clinically meaningful age groups. Results: Multivariate analysis confirmed that older age is associated with GEP class 2 profile. The nonlinear component of the spline model reached borderline significance ( P = .07) and the spline model demonstrated a superior fit compared to standard multivariable linear regression, identifying a transition in GEP class 2 risk from a plateau to an escalation starting around the sixth decade of life. Multivariable age cohort analysis revealed that patients aged 70 to 79 years had a 2.5-fold increase in the odds of a class 2 tumor, while patients ≥ 80 years of age experienced a 3.6-fold increase compared to patients < 50 years of age. Tumor largest basal diameter and ciliary body involvement were also associated with GEP class and PRAME expression. Both linear and nonlinear models revealed no significant association between age and PRAME expression. Conclusions: Older age is strongly associated with GEP class 2 status, with risk escalating in later life, suggesting that advanced age, particularly greater than 60 to 70 years, should prompt a high index of suspicion in the management of uveal nevi or melanoma.